3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 3
1
Phase 1
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leiomyosarcoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostate Cancer Metastatic
1
Mesothelioma, Malignant
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Interventions
Docetaxel
137
Prednisone
120
Abiraterone Acetate
91
Leuprolide
86
enzalutamide
84
Radiotherapy
59
bicalutamide
56
Magnetic Resonance Spectroscopy
54
Goserelin
54
Androgen Antagonists
51
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
47
apalutamide
44
abiraterone
34
Radiosurgery
31
Specimen Handling
30
gallium 68 PSMA-11
29
Gonadotropin-Releasing Hormone
29
cabazitaxel
28
Carboplatin
27
darolutamide
25
Estramustine
24
luprolide acetate gel depot
23
relugolix
22
Metformin
22
Triptorelin Pamoate
20
sipuleucel-T
19
radium Ra 223 dichloride
19
Radiation
19
pembrolizumab
18
deltacortene
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms
×
rucaparib
×
Clear all
NCT03338790
2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2
Completed
292 enrolled
21 charts
NCT03533946
2024-03-13
ROAR
University of Utah
Phase 2
Terminated
7 enrolled
10 charts
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts